6 research outputs found

    ANALYSIS OF THE PRACTICE OF COMBINATIONAL ANTIHYPERTENSION THERAPY BY THE DATA FROM TWO OUTPATIENT REGISTRIES

    Get PDF
    Aim. To investigate on the ways antihypertension drugs (AD) prescription, including, firstly, combinational therapy, in real conditions, by the data from two outpatient registries done in district polyclinics of Ryazan city (RECVASA) and in specialized scientific center in Moscow (PROFILE).Material and methods. To the RECVAZA registry, 3690 patients were included, with cardiovascular diseases, and in 3648 (98,9%) arterial hypertension was diagnosed. Among 1531 patient’s data included into PROFILE registry during August 2011 —August 2015, hypertension was diagnosed in 1230 (80,3%). Mean age of RECVASA and PROFILE patients was 66,3±12,8 и 63,7±11,4, respectively. In overall data, males and females ratio were 28% and 72%, respectively, in RECVASA, and 54% and 46%, resp., in PROFILE.Results. In comparative analysis of the registries, it was found that RECVASA patients were older, and women predominated (72%). Hypertension was diagnosed in almost 100%, was more severe and more comorbid. By the number of prescribed AD, both registries were almost identical: every third patient was prescribed 2 drugs, every fourth — 3, every fifth was taking 1 drug. Fixed combinations of AD were used in 15%, in both registries. The target blood pressure profile was reached in 26,1% of hypertension patients in RECVASA and in 37,6% in PROFILE; in hypertension of 3rd degree — in 21,9% and 34,2% cases, respectively.Conclusion. In generally analogical approaches to AD, matching with current clinical guidelines, final result of treatment in terms of reached target blood pressure values, was significantly better in specialized cardiological center. This, probably, reflects better adherence to therapy in PROFILE patients

    Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

    No full text
    corecore